NW Bio Q3 Loss $28.8M, Cash Down to $725K, Going Concern Reaffirmed
NWBO is trading near its 52-week low of $0.138 (13% above the low).
Summary
NW Bio posted a $28.8M Q3 loss with only $725K of cash left and repeated its going concern warning, while converting another $5.0M of notes into 36.3M shares after quarter-end.
Key Events · Earnings and Guidance · NWBO
-
Q3 Loss Widens, Cash Nearly Gone
Net loss was $28.8M for the three months and $41.1M for the nine months ended September 30, 2026, with cash and equivalents down to $725K from $3.04M at December 31, 2025.
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date, citing recurring operating losses and operating cash flow deficits.
-
Debt Conversions Drive Share Growth
The company converted $21.5M of convertible notes, including $3.8M of accrued interest, into 117.4M shares at a weighted average $0.18 in the first nine months; another $5.0M converted into 36.3M shares between October 1 and November 10, 2026.
-
New $5.5M Streeterville Loan
On October 26, 2026 the company signed a $5,505,000 commercial loan with a 22-month term, 8% interest, a 10% original issue discount and no repayments for the first eight months.
Analysis · NWBO · Life Sciences
Northwest Biotherapeutics ended September with just $725K of cash against a $28.8M quarterly loss and $41.1M nine-month loss, and management again states substantial doubt about continuing as a going concern for at least a year. The company is staying alive by converting debt into stock: $21.5M of convertible notes became 117.4M shares in the first nine months, and another $5.0M converted into 36.3M shares between October 1 and November 10, 2026. That pushed shares outstanding to 1,811,970,770 by November 10 from 1,762.1M at quarter-end. The $5,505,000 Streeterville loan signed October 26, 2026 buys runway but carries a 10% original issue discount and 8% interest. The DCVax-L UK MAA remains under MHRA review with no interim updates planned, so the equity story still hinges on that decision and on continued access to dilutive financing.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NWBO was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $266.9M. The 52-week trading range was $0.14 to $0.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.